Replies to post #188024 on Biotech Values

[drbio45]

The proportion of patients with 3 lines of vision is the more important endpoint.

I know of Ophthotech having some vision improvement in a randomized trial vs lucentis. Are the other drugs you mention in placebo controlled trials or open label?